Catheter Precision, Inc. VTAK

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NYSE

The registrant (together with our consolidated operating subsidiary, the "Company" or "Catheter") was incorporated under the name "Ra Medical Systems, Inc." as a Delaware corporation in July 2018. A predecessor had been incorporated in California in September of 2002, but was reincorporated in 2018 in connection with our initial public offering. The Company was initially formed to develop, commercialize and market an excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases, including the DABRA product line.

On January 9, 2023, the Company merged with Catheter Precision, Inc., or "Old Catheter", a privately-held Delaware corporation (the "Merger"), and the business of Old Catheter became a wholly owned subsidiary of the Company, which today is our only operating subsidiary. Following the Merger, we discontinued the Company's legacy lines of business and the use of any of its DABRA-related assets. For further information about these historical lines of business, see "Item 1. Business" of the Company's Form 10-K for the fiscal year ended December 31, 2021. Since the Merger, we have shifted the focus of our operations to Old Catheter's product lines. Accordingly, our current activities primarily relate to Old Catheter's historical business which comprises the design, manufacture and sale of new and innovative medical technologies focused in the field of cardiac electrophysiology, or "EP."

Last close 0.21 2026-09-04
Market cap $3.0M 2026-06-30 share count
52-week range 0.19 - 3.20

Valuation FY2025 figures against the last close

P/S3.7x
P/E
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $819.0K$420.0K$442.0K$14.0K$22.0K$259.0K$7.2M$6.3M$5.9M
Cost of revenue $63.0K$42.0K$30.0K$161.0K$1.6M$2.2M$8.8M$4.2M$4.2M
Gross profit $756.0K$378.0K$412.0K-$147.0K-$1.5M-$1.9M-$1.7M$2.1M$1.7M
R&D $272.0K$475.0K$6.4M$12.3M$9.0M$4.5M$2.8M$4.5M
SG&A $12.1M$11.3M$17.1M$16.2M$15.5M$24.5M$51.5M$30.4M$14.9M
Total operating expenses $21.9M$11.6M$78.5M$26.8M$27.7M$33.5M$56.1M$33.2M$19.5M
Operating income -$21.1M-$11.2M-$78.1M-$27.0M-$29.3M-$35.4M-$57.7M-$31.2M-$17.8M
Interest expense $108.0K$250.0K$14.0K$4.0K
Pre-tax income -$19.5M-$13.5M-$70.6M-$26.9M-$27.3M-$35.3M-$56.9M-$30.8M-$17.8M
Income tax $1.8M$3.1M$0$3.0K$4.0K$7.0K$15.0K$10.0K$1.0K
Net income -$17.2M-$16.6M-$70.6M-$26.9M-$25.1M-$36.0M-$57.0M-$30.8M-$17.8M
EPS, basic -15.90-126.91-129.88-25.98-248.22
EPS, diluted -25.98-248.22-21.22-108.28-3.34-2.35
Shares, diluted (wtd. avg.) $1.1M$171.8K$549.5K$1.0M$101.0K

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $88.0K$2.9M$3.6M$15.9M$15.0M$23.9M$14.6M$64.3M$8.2M$3.9M
Receivables $155.0K$70.0K$137.0K$0$21.0K$24.0K$786.0K$1.3M$517.0K
Inventory $86.0K$33.0K$44.0K$0$986.0K$877.0K$2.8M$2.1M$1.2M
Total current assets $390.0K$3.3M$4.2M$16.8M$17.1M$27.6M$36.0M$69.2M$10.0M
Property, plant and equipment $64.0K$91.0K$70.0K$0$1.8M$2.5M$5.0M$4.8M$1.2M
Goodwill $0$0
Other intangibles $15.2M$24.3M$26.3M$0
Total assets $15.9M$27.8M$30.7M$16.8M$21.0M$33.4M$44.1M$74.0M$11.3M
Accounts payable $1.5M$230.0K$464.0K$92.0K$988.0K$471.0K$1.5M$1.1M$426.0K
Total current liabilities $3.9M$2.2M$2.5M$7.6M$5.4M$7.8M$6.8M$6.0M$2.6M
Long-term debt $3.1M$558.0K$850.0K
Total liabilities $9.2M$16.0M$9.5M$7.6M$7.4M$12.3M$10.9M$7.3M$18.9M
Retained earnings -$309.5M-$292.4M-$275.7M-$205.1M-$178.3M-$153.2M-$117.2M-$60.2M-$29.4M
Total equity $7.1M$11.8M$21.2M$9.3M$13.7M$21.1M$33.1M$66.7M-$7.6M-$380.0K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$8.3M-$9.3M-$20.6M-$22.6M-$27.6M-$28.3M-$33.2M-$18.5M-$5.5M
Depreciation and amortisation $2.1M$2.1M$2.1M$179.0K$1.0M$1.6M$1.4M$624.0K$218.0K
Stock-based compensation $338.0K$54.0K$1.2M$447.0K$2.2M$4.1M$23.5M$14.7M$12.7M
Capital expenditure $17.0K$67.0K$76.0K$17.0K$265.0K$67.0K$268.0K$582.0K$547.0K
Investing cash flow $167.0K-$67.0K-$61.0K$21.0K$3.8M$15.9M-$16.0M-$582.0K-$547.0K
Financing cash flow $5.3M$8.6M$8.4M$23.4M$15.0M$21.7M-$526.0K$75.2M$10.4M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-014220.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $116.27B 36.1x 11.2%
MMM 3M CO $86.93B 28.1x 1.5%
BSX BOSTON SCIENTIFIC CORP $69.27B 24.6x 19.9%
BDX BECTON DICKINSON & CO $50.32B 31.7x 8.2%
DXCM DEXCOM INC $33.17B 42.1x 15.6%
RMD RESMED INC $32.94B 21.9x 9.9%
MDLN Medline Inc. $31.35B 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $23.93B 50.1x 6.3%